“NorthStar has quickly achieved several key milestones in advancing our strategically planned RadioGenix System roll-out,” said George P. Messina, Chairman and CEO of NorthStar. “First, the FDA approval of our Beloit manufacturing facility enables us to scale up production and expand capacity to meet anticipated customer demand. The approval came well in advance of the anticipated FDA action date. Second, we are also very pleased to announce that the commercial launch of the RadioGenix System has commenced, with the first contract signed and the first installation scheduled at a customer site. This important event marks another milestone in NorthStar’s commitment to provide the United States healthcare system with a reliable, domestic non-uranium based Mo-99 supply for production of the important medical diagnostic imaging radioisotope, technetium-99m. We anticipate shipping additional RadioGenix Systems as potential customers receive licensing amendments for their sites, and look forward to sharing our progress.” Read the full story here.
- Wisconsin State Journal: Blexx, a startup whose tool destroys used hypodermic needles, wins Madison pitch contest.November 9, 2018
- WisBusiness: Elevator Pitch Olympics features life science startupsNovember 9, 2018
- Kelly Lietz on LinkedIn: Identifying Win-Win Opportunities in Startup InvestingNovember 9, 2018
- InsideWis: Tech, art and design of ‘smart’ cities converge through Wisconsin companyNovember 6, 2018
- Venture Investors director John Neis to join Tech Council’s ‘Investor Hall of Fame’November 2, 2018